Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
ISRN Inflammation|September 20, 2013
Anti-inflammatory effects of urocanic Acid derivatives in models ex vivo and in vivo of inflammatory bowel diseaseArthur Kammeyer, Charlotte P Peters, Sybren L Meijer, et al.
Nederlands Tijdschrift Voor Geneeskunde|May 4, 2019
[Acute liver failure due to food supplements]Charlotte P Peters, Caroline M den Hoed, Sandra Coenen, et al.
Frontiers in Immunology|May 9, 2012
Functional Differences between Human NKp44(-) and NKp44(+) RORC(+) Innate Lymphoid CellsKerim Hoorweg, Charlotte P Peters, Ferry Cornelissen, et al.
Transfusion|May 18, 2011
Accumulation of bioactive lipids during storage of blood products is not cell but plasma derived and temperature dependentAlexander P J Vlaar, Wim Kulik, Rienk Nieuwland, et al.
Nature Immunology|September 13, 2011
Human IL-25- and IL-33-responsive type 2 innate lymphoid cells are defined by expression of CRTH2 and CD161Jenny M Mjösberg, Sara Trifari, Natasha K Crellin, et al.
World Journal of Gastroenterology|March 15, 2014
ATG16L1 and NOD2 polymorphisms enhance phagocytosis in monocytes of Crohn's disease patientsSimone C S Wolfkamp, Caroline Verseyden, Esther W M Vogels, et al.
Immunity|October 16, 2012
The transcription factor GATA3 is essential for the function of human type 2 innate lymphoid cellsJenny Mjösberg, Jochem Bernink, Korneliusz Golebski, et al.
Inflammatory Bowel Diseases|April 5, 2013
Ten years of infliximab for Crohn's disease: outcome in 469 patients from 2 tertiary referral centersEmma J Eshuis, Charlotte P Peters, Adriaan A van Bodegraven, et al.
Inflammatory Bowel Diseases|January 1, 2014
Effects of infliximab retreatment after consecutive discontinuation of infliximab and adalimumab in refractory Crohn's diseaseJohannan F Brandse, Charlotte P Peters, Krisztina B Gecse, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|August 2, 2014
Screening prior to biological therapy in Crohn's disease: adherence to guidelines and prevalence of infections. Results from a multicentre retrospective studyMike van der Have, Tim D G Belderbos, Herma H Fidder, et al.
Pageof 2